This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox.

You’re back. We’re sort of back. It’s Day 2 of JPM and we’re definitely not exhausted or delirious yet.

This is Elaine Chen, Adam Feuerstein, Matt Herper, and Allison DeAngelis again. We’ve got a lot more news today, so let’s get to it.

The next test for Kite Pharma — and Gilead

It’s anito-cel, the CAR-T therapy for multiple myeloma that Gilead is developing in partnership with Arcellx. Gilead submitted the therapy to the FDA sometime before the end of December, Cindy Perettie, executive vice president of Kite Pharma, the cell therapy division of Gilead, told STAT at a Gilead media breakfast.

Continue to STAT+ to read the full story…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. My colleagues will be in Orlando later this week for the American Society of Hematology meeting. Sign up for their newsletter to stay on top of the news from the conference. We’re also holding an event there on Friday.

Fight around hospital drug discount program escalates with new lawsuit

The American Hospital Association and several hospital systems have filed a lawsuit against the Trump administration, seeking to halt an upcoming pilot program for a controversial drug discount program.

Continue to STAT+ to read the full story…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, we just had our first snow of the season in Chicago, I just ordered a pie for Thanksgiving, and I’m still in denial that the year is almost ending.

Onto the news today.

Continue to STAT+ to read the full story…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. It seems everyone I know has been getting sick lately — hope you are all taking care of yourselves! Onto the news today.

BridgeBio notches another Phase 3 win

BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant hypocalcemia type 1, a rare genetic condition that causes low calcium levels in the blood.

Continue to STAT+ to read the full story…